May be considered by a clinician for a defined condition after standard options, evidence quality and the patient’s medication history are reviewed.
LONGEVITY & HEALTHY AGING / PRACTITIONER-GUIDED
Low-dose naltrexone (LDN)
EvidenceEvidence in contexti
Limited and condition-specific human evidence; no broad wellness or longevity indication is established.
RegulatoryProduct-specifici
Naltrexone is FDA-approved at other doses; low-dose use is off-label

Limited and condition-specific human evidence; no broad wellness or longevity indication is established.
Naltrexone is FDA-approved at other doses; low-dose use is off-label
WHO MAY BE CONSIDERED
Eligibility starts with your complete health context.
- ✓A specific clinical goal is documented
- ✓Opioid exposure and withdrawal risk are fully reviewed
- ✓The patient understands the off-label evidence limits
WHAT A PRACTITIONER REVIEWS
The information that shapes the decision.
- All opioid, tramadol and cough or diarrhea medicines
- Liver history and relevant labs
- Pain, sleep, mood and a defined trial outcome
IMPORTANT SAFETY INFORMATION
Reasons treatment may not be appropriate.
- !Naltrexone can precipitate opioid withdrawal and block opioid pain treatment.
- !Liver disease and medication interactions require review.
- !LDN should not be marketed as a cure-all or substituted for diagnosis and established care.
ORIGINAL SOURCES
Review the evidence behind the option.
YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools